ASP Isotopes SEC Filings

ASP Isotopes, through its wholly owned subsidiary Quantum Leap Energy (QLE), plans to establish QLE’s new global corporate headquarters in Austin, Texas. The move is intended to strengthen its Texas presence and position the development-stage nuclear fuels company closer to its U.S. customer base.

QLE also plans a significant operational presence in Texas, working with Fermi America under an existing memorandum of understanding to pursue a joint venture for a high-assay low-enriched uranium enrichment research and commercial production facility linked to Fermi America’s hypergrid campus in Amarillo. This would be developed alongside ASP Isotopes’ planned commercial facility for stable isotopes and advanced nuclear materials.

The announcement highlights Texas’ supportive regulatory and business environment for nuclear power and notes U.S. Department of Energy estimates that domestic demand for HALEU could reach 50 metric tons per year by 2035 and 500 metric tons per year by 2050, underscoring the potential market for advanced nuclear fuels.

BNP Paribas Asset Management UK Ltd has filed an amended Schedule 13G reporting beneficial ownership of 944,326 shares of ASP Isotopes Inc. common stock, representing 0.9% of the outstanding class as of December 31, 2025. The firm reports sole voting and dispositive power over all of these shares and confirms they are held in the ordinary course of business, not to change or influence control of ASP Isotopes.

ASP Isotopes Inc. agreed to invest in biotechnology company Opeongo by purchasing 4,356,918 shares of Opeongo’s Series Seed-1 Preferred Stock at an original purchase price of $2.2952 per share. The preferred stock is convertible into Opeongo common stock and carries anti-dilution protections, voting rights, and the ability for Series Seed-1 holders to elect a dedicated director while enough shares remain outstanding.

ASP Isotopes and other investors also received veto rights over certain major Opeongo corporate actions and contractual protections through investors’ rights, right of first refusal and co-sale, and voting agreements. Within thirty days after January 26, 2026, ASP Isotopes and Opeongo are obligated to negotiate a draft supply agreement giving ASP Isotopes a right of first offer for medical isotope supply tied to Opeongo’s future pharmaceutical products.

The Vanguard Group reported a passive ownership stake in ASP Isotopes Inc common stock on a Schedule 13G. Vanguard beneficially owns 6,406,244 shares, representing 5.77% of the outstanding common stock. It has shared voting power over 873,110 shares and shared dispositive power over all 6,406,244 shares, with no sole voting or dispositive authority.

Vanguard states the shares are held in the ordinary course of business, not to change or influence control of ASP Isotopes. Following an internal realignment on January 12, 2026, certain Vanguard subsidiaries are expected to report beneficial ownership separately while pursuing the same investment strategies as before.

ASP Isotopes Inc. filed a current report to share that it issued a press release providing a production update on the Helium Project of Renergen Limited. The press release, dated January 29, 2026, is attached as Exhibit 99.1 and is incorporated by reference into the report.

The information is furnished under Regulation FD, meaning it is intended to ensure broad, non-selective disclosure. The company also notes that the press release contains forward-looking statements covered by the Private Securities Litigation Reform Act safe harbor provisions.

Encompass Capital Advisors LLC filed a Schedule 13G reporting a significant passive ownership stake in ASP Isotopes Inc. common stock. The firm and its managing member, Todd J. Kantor, together report beneficial ownership of 6,413,362 shares, representing 5.13% of ASP Isotopes’ outstanding common stock as of the event date 01/16/2026.

Both Encompass and Kantor report shared voting and dispositive power over all 6,413,362 shares and no sole power to vote or dispose of any shares. They certify that the securities were not acquired and are not held for the purpose or effect of changing or influencing control of ASP Isotopes, indicating a passive investment intent. A joint filing agreement confirms the Schedule 13G is filed on behalf of both reporting persons.

ASP Isotopes Inc. reported leadership changes tied to its closing of the previously announced acquisition of Renergen Limited on January 6, 2026. Renergen’s Chief Executive Officer, Stefano Marani, has been appointed President, Electronics and Space of ASP Isotopes, and Renergen’s Chief Operating Officer, Nick Mitchell, has been appointed Co-Chief Operating Officer of ASP Isotopes.

The company expects to enter into employment agreements providing Mr. Marani a base salary of $550,000 per year and Mr. Mitchell $400,000 per year, each with a target annual discretionary bonus equal to 50% of base salary, payable in a mix of cash and common stock. Each executive has been approved for a grant of 700,000 shares of common stock, vesting in eight equal installments over four years, with 87,500 shares vesting on each six‑month anniversary of employment, subject to continued service.

The stock awards are being made under ASP Isotopes’ inducement equity incentive plans in line with Nasdaq Listing Rule 5635(c)(4), and both executives will also be eligible for annual equity awards under the company’s 2022 Equity Incentive Plan. Due to prior transactions between ASP Isotopes and Renergen, including a $30 million bridge loan agreement, the company notes that Mr. Marani and Mr. Mitchell may be deemed to have a direct or indirect material interest in such dealings for related‑party disclosure purposes.

ASP Isotopes Inc. completed its previously announced acquisition of Renergen Limited on January 6, 2026. ASP Isotopes acquired all issued Renergen ordinary shares via a South African court-approved scheme of arrangement, paying with shares of its own common stock.

Renergen shareholders received 0.09196 ASP Isotopes common shares for each Renergen ordinary share, resulting in the issuance of 14,270,000 new ASP Isotopes shares. Following the deal, Renergen became a direct, wholly owned subsidiary, and its shares will be delisted from the Johannesburg Stock Exchange, the Australian Securities Exchange and A2X, while ASP Isotopes stock remains listed on Nasdaq and the JSE.

Renergen executives are joining ASP Isotopes’ leadership, with CEO Stefano Marani becoming President, Electronics and Space, and COO Nick Mitchell becoming Co-Chief Operating Officer. The consideration shares were issued in an unregistered transaction relying on Rule 802, and ASP Isotopes plans to file required acquired-business financial statements and pro forma information in a later amendment.

ASP Isotopes Inc. reports that the South African Takeover Regulation Panel has issued a compliance certificate for its planned acquisition of Renergen Limited. This clears a key regulatory step so the South African law scheme of arrangement can proceed to implementation. Under the Scheme, Renergen shareholders are to receive 0.09196 new ASP Isotopes shares for each Renergen share held on the record date.

The company outlines a detailed timetable through early January 2026, including suspensions of Renergen trading on the JSE and ASX, the listing of ASP Isotopes consideration shares, the Scheme implementation date, settlement of new shares, and payment of cash for fractional entitlements. The disclosure also highlights cross-border settlement mechanics and reiterates risks that the Scheme may not be implemented as anticipated or that expected benefits from the Renergen acquisition may not be realized.